{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T05:23:33Z","timestamp":1790659413779,"version":"4.1.0"},"reference-count":73,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2024,9,1]],"date-time":"2024-09-01T00:00:00Z","timestamp":1725148800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,9,1]],"date-time":"2024-09-01T00:00:00Z","timestamp":1725148800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,7,11]],"date-time":"2024-07-11T00:00:00Z","timestamp":1720656000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82,272,865"],"award-info":[{"award-number":["82,272,865"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["cancertreatmentreviews.com","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Cancer Treatment Reviews"],"published-print":{"date-parts":[[2024,9]]},"DOI":"10.1016\/j.ctrv.2024.102770","type":"journal-article","created":{"date-parts":[[2024,5,22]],"date-time":"2024-05-22T12:19:10Z","timestamp":1716380350000},"page":"102770","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":14,"special_numbering":"C","title":["Revisiting ovarian function suppression with GnRH agonists for premenopausal women with breast cancer: Who should use and the impact on survival outcomes"],"prefix":"10.1016","volume":"129","author":[{"given":"Linxiaoxi","family":"Ma","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Benlong","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiong","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ctrv.2024.102770_b0005","doi-asserted-by":"crossref","first-page":"170","DOI":"10.4103\/0974-1208.142476","article-title":"Gonadotropin-releasing hormone analogs: understanding advantages and limitations","volume":"7","author":"Kumar","year":"2014","journal-title":"J Hum Reprod Sci"},{"key":"10.1016\/j.ctrv.2024.102770_b0010","first-page":"29","article-title":"The molecular mechanism of action of gonadotropin releasing hormone (GnRH) in the pituitary","volume":"43","author":"Conn","year":"1987","journal-title":"Recent Prog Horm Res"},{"key":"10.1016\/j.ctrv.2024.102770_b0015","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1093\/oxfordjournals.humrep.a136732","article-title":"Mechanism of GnRH action in gonadotrophs","volume":"3","author":"Clayton","year":"1988","journal-title":"Hum Reprod"},{"key":"10.1016\/j.ctrv.2024.102770_b0020","doi-asserted-by":"crossref","first-page":"861","DOI":"10.1016\/S0959-8049(02)00810-9","article-title":"The use of gonadotrophin-releasing hormone (GnRH) agonists in early and advanced breast cancer in pre- and perimenopausal women","volume":"39","author":"Robertson","year":"2003","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.ctrv.2024.102770_b0025","doi-asserted-by":"crossref","first-page":"1216","DOI":"10.1016\/j.annonc.2021.06.023","article-title":"Customizing local and systemic therapies for women with early breast cancer: the St. Gallen International Consensus Guidelines for treatment of early breast cancer 2021","volume":"32","author":"Burstein","year":"2021","journal-title":"Ann Oncol"},{"key":"10.1016\/j.ctrv.2024.102770_b0030","doi-asserted-by":"crossref","first-page":"594","DOI":"10.6004\/jnccn.2023.0031","article-title":"Insights: breast cancer, version 4.2023","volume":"21","author":"Gradishar","year":"2023","journal-title":"J Natl Compr Canc Netw"},{"key":"10.1016\/j.ctrv.2024.102770_b0035","doi-asserted-by":"crossref","first-page":"1097","DOI":"10.1016\/j.annonc.2022.07.007","article-title":"ESO-ESMO fifth international consensus guidelines for breast cancer in young women (BCY5)","volume":"33","author":"Paluch-Shimon","year":"2022","journal-title":"Ann Oncol"},{"key":"10.1016\/j.ctrv.2024.102770_b0040","doi-asserted-by":"crossref","unstructured":"Jiang Z, Li J, Chen J, Liu Y, Wang K, Nie J, et al. Chinese Society of Clinical Oncology (CSCO) Breast Cancer Guidelines 2022. Transl Breast Cancer Res 2022;3. doi: doi: 10.21037\/tbcr-22-21.","DOI":"10.21037\/tbcr-22-13"},{"key":"10.1016\/j.ctrv.2024.102770_b0045","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1200\/JCO.18.01160","article-title":"Adjuvant endocrine therapy for women with hormone receptor-positive breast cancer: ASCO Clinical Practice Guideline Focused Update","volume":"37","author":"Burstein","year":"2019","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ctrv.2024.102770_b0050","doi-asserted-by":"crossref","first-page":"436","DOI":"10.1056\/NEJMoa1412379","article-title":"Adjuvant ovarian suppression in premenopausal breast cancer","volume":"372","author":"Francis","year":"2015","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ctrv.2024.102770_b0055","doi-asserted-by":"crossref","first-page":"434","DOI":"10.1200\/JCO.19.00126","article-title":"Adding ovarian suppression to tamoxifen for premenopausal breast cancer: a randomized phase III trial","volume":"38","author":"Kim","year":"2020","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ctrv.2024.102770_b0060","doi-asserted-by":"crossref","first-page":"1370","DOI":"10.1200\/JCO.22.01065","article-title":"Adjuvant endocrine therapy in premenopausal breast cancer: 12-year results from SOFT","volume":"41","author":"Francis","year":"2023","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ctrv.2024.102770_b0065","doi-asserted-by":"crossref","first-page":"4864","DOI":"10.1200\/JCO.23.00557","article-title":"Adding ovarian suppression to tamoxifen for premenopausal women with hormone receptor-positive breast cancer after chemotherapy: an 8-year follow-up of the ASTRRA trial","volume":"41","author":"Baek","year":"2023","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ctrv.2024.102770_b0070","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2021.39.15_suppl.e18581","article-title":"Recurrence risk in early breast cancer as defined by clinicopathologic features","volume":"39","author":"Sheffield","year":"2021","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ctrv.2024.102770_b0075","doi-asserted-by":"crossref","first-page":"1836","DOI":"10.1056\/NEJMoa1701830","article-title":"20-year risks of breast-cancer recurrence after stopping endocrine therapy at 5 years","volume":"377","author":"Pan","year":"2017","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ctrv.2024.102770_b0080","doi-asserted-by":"crossref","first-page":"1376","DOI":"10.1200\/JCO.22.01064","article-title":"Adjuvant exemestane with ovarian suppression in premenopausal breast cancer: Long-term follow-up of the combined TEXT and SOFT trials","volume":"41","author":"Pagani","year":"2023","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ctrv.2024.102770_b0085","doi-asserted-by":"crossref","first-page":"4071","DOI":"10.1200\/JCO.21.02844","article-title":"Twenty-year benefit from adjuvant goserelin and tamoxifen in premenopausal patients with breast cancer in a controlled randomized clinical trial","volume":"40","author":"Johansson","year":"2022","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ctrv.2024.102770_b0090","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1056\/NEJMoa1803164","article-title":"Tailoring adjuvant endocrine therapy for premenopausal breast cancer","volume":"379","author":"Francis","year":"2018","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ctrv.2024.102770_b0095","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1200\/JCO.2023.41.16_suppl.503","article-title":"Effects of ovarian ablation or suppression on breast cancer recurrence and survival: patient-level meta-analysis of 14,993 pre-menopausal women in 25 randomized trials","volume":"41","author":"Gray","year":"2023","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ctrv.2024.102770_b0100","doi-asserted-by":"crossref","first-page":"3948","DOI":"10.1200\/JCO.2014.55.6993","article-title":"Phase III comparison of tamoxifen versus tamoxifen plus ovarian function suppression in premenopausal women with node-negative, hormone receptor-positive breast cancer (E-3193, INT-0142): a trial of the eastern cooperative oncology group","volume":"32","author":"Tevaarwerk","year":"2014","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ctrv.2024.102770_b0105","doi-asserted-by":"crossref","first-page":"895","DOI":"10.1016\/j.ejca.2005.12.013","article-title":"Adjuvant goserelin in pre-menopausal patients with early breast cancer: Results from the ZIPP study","volume":"42","author":"Baum","year":"2006","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.ctrv.2024.102770_b0110","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1016\/j.ejca.2019.05.004","article-title":"Adjuvant zoledronic acid and letrozole plus ovarian function suppression in premenopausal breast cancer: HOBOE phase 3 randomised trial","volume":"118","author":"Perrone","year":"2019","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.ctrv.2024.102770_b0115","doi-asserted-by":"crossref","unstructured":"Adjuvant Breast Cancer Trials Collaborative Group. Ovarian ablation or suppression in premenopausal early breast cancer: results from the international adjuvant breast cancer ovarian ablation or suppression randomized trial. J Natl Cancer Inst 2007;99:516-25. doi: 10.1093\/jnci\/djk109.","DOI":"10.1093\/jnci\/djk109"},{"key":"10.1016\/j.ctrv.2024.102770_b0120","doi-asserted-by":"crossref","first-page":"5973","DOI":"10.1200\/JCO.2005.05.551","article-title":"Chemoendocrine therapy for premenopausal women with axillary lymph node-positive, steroid hormone receptor-positive breast cancer: results from INT 0101 (E5188)","volume":"23","author":"Davidson","year":"2005","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ctrv.2024.102770_b0125","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1093\/annonc\/mdu544","article-title":"Zoledronic acid combined with adjuvant endocrine therapy of tamoxifen versus anastrozol plus ovarian function suppression in premenopausal early breast cancer: final analysis of the Austrian Breast and Colorectal Cancer Study Group Trial 12","volume":"26","author":"Gnant","year":"2015","journal-title":"Ann Oncol"},{"key":"10.1016\/j.ctrv.2024.102770_b0130","doi-asserted-by":"crossref","first-page":"582","DOI":"10.4103\/0019-509X.175301","article-title":"The outcome effect of double-hormonal therapy in premenopausal breast cancer patients with high nodal-status: Result of a prospective randomized trial","volume":"51","author":"Uslu","year":"2014","journal-title":"Indian J Cancer"},{"key":"10.1016\/j.ctrv.2024.102770_b0135","doi-asserted-by":"crossref","first-page":"2225","DOI":"10.1093\/annonc\/mdx285","article-title":"Concurrent and sequential initiation of ovarian function suppression with chemotherapy in premenopausal women with endocrine-responsive early breast cancer: an exploratory analysis of TEXT and SOFT","volume":"28","author":"Regan","year":"2017","journal-title":"Ann Oncol"},{"key":"10.1016\/j.ctrv.2024.102770_b0140","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1001\/jamaoncol.2021.6214","article-title":"Effects of gonadotropin-releasing hormone analogs on ovarian function against chemotherapy-induced gonadotoxic effects in premenopausal women with breast cancer in China: a randomized clinical trial","volume":"8","author":"Zong","year":"2022","journal-title":"JAMA Oncol"},{"key":"10.1016\/j.ctrv.2024.102770_b0145","doi-asserted-by":"crossref","first-page":"2632","DOI":"10.1001\/jama.2015.17291","article-title":"Ovarian suppression with triptorelin during adjuvant breast cancer chemotherapy and long-term ovarian function, pregnancies, and disease-free survival: a randomized clinical trial","volume":"314","author":"Lambertini","year":"2015","journal-title":"JAMA"},{"key":"10.1016\/j.ctrv.2024.102770_b0150","doi-asserted-by":"crossref","first-page":"1811","DOI":"10.1093\/annonc\/mdx184","article-title":"GnRH agonist for protection against ovarian toxicity during chemotherapy for early breast cancer: the Anglo Celtic Group OPTION trial","volume":"28","author":"Leonard","year":"2017","journal-title":"Ann Oncol"},{"key":"10.1016\/j.ctrv.2024.102770_b0155","doi-asserted-by":"crossref","first-page":"923","DOI":"10.1056\/NEJMoa1413204","article-title":"Goserelin for ovarian protection during breast-cancer adjuvant chemotherapy","volume":"372","author":"Moore","year":"2015","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ctrv.2024.102770_b0160","doi-asserted-by":"crossref","unstructured":"Early Breast Cancer Trialists' Collaborative G. Aromatase inhibitors versus tamoxifen in premenopausal women with oestrogen receptor-positive early-stage breast cancer treated with ovarian suppression: a patient-level meta-analysis of 7030 women from four randomised trials. Lancet Oncol 2022;23:382-92. doi: 10.1016\/S1470-2045(21)00758-0.","DOI":"10.1016\/S1470-2045(21)00758-0"},{"key":"10.1016\/j.ctrv.2024.102770_b0165","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1038\/s41523-023-00509-2","article-title":"Type of adjuvant endocrine therapy and disease-free survival in patients with early HR-positive\/HER2-positive BC: analysis from the phase III randomized ShortHER trial","volume":"9","author":"Dieci","year":"2023","journal-title":"npj Breast Cancer"},{"key":"10.1016\/j.ctrv.2024.102770_b0170","article-title":"Ribociclib and endocrine therapy as adjuvant treatment in patients with HR+\/HER2- early breast cancer: primary results from the phase III NATALEE trial","volume":"41","author":"Stroyakovskiy","year":"2023","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ctrv.2024.102770_b0175","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1016\/S1470-2045(22)00694-5","article-title":"Abemaciclib plus endocrine therapy for hormone receptor-positive, HER2-negative, node-positive, high-risk early breast cancer (monarchE): results from a preplanned interim analysis of a randomised, open-label, phase 3 trial","volume":"24","author":"Johnston","year":"2023","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.ctrv.2024.102770_b0180","doi-asserted-by":"crossref","first-page":"S1382","DOI":"10.1016\/j.annonc.2022.08.008","article-title":"LBA14 Impact of age, recurrence score (RS) and ovarian function suppression (OFS) on endocrine response to short preoperative endocrine therapy (ET): analysis of ADAPT and ADAPTcycle trials","volume":"33","author":"Gluz","year":"2022","journal-title":"Ann Oncol"},{"key":"10.1016\/j.ctrv.2024.102770_b0185","doi-asserted-by":"crossref","first-page":"3917","DOI":"10.1200\/JCO.2009.24.9565","article-title":"Phase II trial of anastrozole plus goserelin in the treatment of hormone receptor-positive, metastatic carcinoma of the breast in premenopausal women","volume":"28","author":"Carlson","year":"2010","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ctrv.2024.102770_b0190","doi-asserted-by":"crossref","first-page":"2705","DOI":"10.1200\/JCO.2009.26.5884","article-title":"Phase II parallel group study showing comparable efficacy between premenopausal metastatic breast cancer patients treated with letrozole plus goserelin and postmenopausal patients treated with letrozole alone as first-line hormone therapy","volume":"28","author":"Park","year":"2010","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ctrv.2024.102770_b0195","doi-asserted-by":"crossref","first-page":"1707","DOI":"10.3892\/or.2013.2312","article-title":"Efficacy of goserelin plus anastrozole in premenopausal women with advanced or recurrent breast cancer refractory to an LH-RH analogue with tamoxifen: results of the JMTO BC08-01 phase II trial","volume":"29","author":"Nishimura","year":"2013","journal-title":"Oncol Rep"},{"key":"10.1016\/j.ctrv.2024.102770_b0200","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1056\/NEJMoa1903765","article-title":"Overall survival with ribociclib plus endocrine therapy in breast cancer","volume":"381","author":"Im","year":"2019","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ctrv.2024.102770_b0205","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1186\/s13058-021-01463-2","article-title":"Abemaciclib plus fulvestrant in hormone receptor-positive, human epidermal growth factor receptor 2-negative advanced breast cancer in premenopausal women: subgroup analysis from the MONARCH 2 trial","volume":"23","author":"Neven","year":"2021","journal-title":"Breast Cancer Res"},{"key":"10.1016\/j.ctrv.2024.102770_b0210","doi-asserted-by":"crossref","first-page":"1028","DOI":"10.1634\/theoncologist.2017-0072","article-title":"Palbociclib combined with fulvestrant in premenopausal women with advanced breast cancer and prior progression on endocrine therapy: PALOMA-3 results","volume":"22","author":"Loibl","year":"2017","journal-title":"Oncologist"},{"key":"10.1016\/j.ctrv.2024.102770_b0215","doi-asserted-by":"crossref","unstructured":"Early Breast Cancer Trialists' Collaborative G, Peto R, Davies C, Godwin J, Gray R, Pan HC, et al. Comparisons between different polychemotherapy regimens for early breast cancer: meta-analyses of long-term outcome among 100,000 women in 123 randomised trials. Lancet 2012;379:432-44. doi: 10.1016\/S0140-6736(11)61625-5.","DOI":"10.1016\/S0140-6736(11)61625-5"},{"key":"10.1016\/j.ctrv.2024.102770_b0220","doi-asserted-by":"crossref","unstructured":"Early Breast Cancer Trialists' Collaborative G. Increasing the dose intensity of chemotherapy by more frequent administration or sequential scheduling: a patient-level meta-analysis of 37 298 women with early breast cancer in 26 randomised trials. Lancet 2019;393:1440-52. doi: 10.1016\/S0140-6736(18)33137-4.","DOI":"10.1016\/S0140-6736(18)33137-4"},{"key":"10.1016\/j.ctrv.2024.102770_b0225","doi-asserted-by":"crossref","first-page":"476","DOI":"10.1016\/S1470-2045(21)00007-3","article-title":"70-gene signature as an aid for treatment decisions in early breast cancer: updated results of the phase 3 randomised MINDACT trial with an exploratory analysis by age","volume":"22","author":"Piccart","year":"2021","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.ctrv.2024.102770_b0230","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1056\/NEJMoa1804710","article-title":"Adjuvant Chemotherapy Guided by a 21-Gene Expression Assay in Breast Cancer","volume":"379","author":"Sparano","year":"2018","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ctrv.2024.102770_b0235","doi-asserted-by":"crossref","first-page":"2005","DOI":"10.1056\/NEJMoa1510764","article-title":"Prospective validation of a 21-gene expression assay in breast cancer","volume":"373","author":"Sparano","year":"2015","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ctrv.2024.102770_b0240","doi-asserted-by":"crossref","first-page":"2336","DOI":"10.1056\/NEJMoa2108873","article-title":"21-Gene Assay to Inform Chemotherapy Benefit in Node-Positive Breast Cancer","volume":"385","author":"Kalinsky","year":"2021","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ctrv.2024.102770_b0245","doi-asserted-by":"crossref","first-page":"717","DOI":"10.1056\/NEJMoa1602253","article-title":"70-Gene Signature as an Aid to Treatment Decisions in Early-Stage Breast Cancer","volume":"375","author":"Cardoso","year":"2016","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ctrv.2024.102770_b0250","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1186\/s13058-017-0911-9","article-title":"Prognostic value of PAM50 and risk of recurrence score in patients with early-stage breast cancer with long-term follow-up","volume":"19","author":"Ohnstad","year":"2017","journal-title":"Breast Cancer Res"},{"key":"10.1016\/j.ctrv.2024.102770_b0255","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2023.41.16_suppl.504","article-title":"Evaluation of PAM50 intrinsic subtypes and risk of recurrence (ROR) scores in premenopausal women with early-stage HR+ breast cancer: a secondary analysis of the SOFT trial","volume":"41","author":"Brown","year":"2023","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ctrv.2024.102770_b0260","doi-asserted-by":"crossref","first-page":"2221","DOI":"10.1200\/JCO.2015.64.3171","article-title":"Absolute benefit of adjuvant endocrine therapies for premenopausal women with hormone receptor-positive, human epidermal growth factor receptor 2-negative early breast cancer: TEXT and SOFT trials","volume":"34","author":"Regan","year":"2016","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ctrv.2024.102770_b0265","doi-asserted-by":"crossref","first-page":"e000771","DOI":"10.1136\/esmoopen-2020-000771","article-title":"Gender-specific aspects related to type of fertility preservation strategies and access to fertility care","volume":"5","author":"Perachino","year":"2020","journal-title":"ESMO Open"},{"key":"10.1016\/j.ctrv.2024.102770_b0270","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1093\/jnci\/djy185","article-title":"Final analysis of the Prevention of Early Menopause Study (POEMS)\/SWOG Intergroup S0230","volume":"111","author":"Moore","year":"2019","journal-title":"J Natl Cancer Inst"},{"key":"10.1016\/j.ctrv.2024.102770_b0275","doi-asserted-by":"crossref","first-page":"400","DOI":"10.1093\/jnci\/djab213","article-title":"Long-term outcomes with pharmacological ovarian suppression during chemotherapy in premenopausal early breast cancer patients","volume":"114","author":"Lambertini","year":"2022","journal-title":"J Natl Cancer Inst"},{"key":"10.1016\/j.ctrv.2024.102770_b0280","doi-asserted-by":"crossref","first-page":"3113","DOI":"10.1200\/JCO.2016.72.0946","article-title":"Treatment efficacy, adherence, and quality of life among women younger than 35 years in the International breast cancer study group TEXT and SOFT adjuvant endocrine therapy trials","volume":"35","author":"Saha","year":"2017","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ctrv.2024.102770_b0285","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1056\/NEJMoa1404037","article-title":"Adjuvant exemestane with ovarian suppression in premenopausal breast cancer","volume":"371","author":"Pagani","year":"2014","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ctrv.2024.102770_b0290","doi-asserted-by":"crossref","first-page":"1601","DOI":"10.1200\/JCO.2015.64.8675","article-title":"Adjuvant tamoxifen plus ovarian function suppression versus tamoxifen alone in premenopausal women with early breast cancer: patient-reported outcomes in the suppression of ovarian function trial","volume":"34","author":"Ribi","year":"2016","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ctrv.2024.102770_b0295","doi-asserted-by":"crossref","first-page":"1426","DOI":"10.1016\/j.psyneuen.2008.08.006","article-title":"Reversibility of the effects of acute ovarian hormone suppression on verbal memory and prefrontal function in pre-menopausal women","volume":"33","author":"Craig","year":"2008","journal-title":"Psychoneuroendocrinology"},{"key":"10.1016\/j.ctrv.2024.102770_b0300","doi-asserted-by":"crossref","first-page":"987","DOI":"10.1016\/j.psyneuen.2009.12.012","article-title":"The interactive effect of acute ovarian suppression and the cholinergic system on visuospatial working memory in young women","volume":"35","author":"Craig","year":"2010","journal-title":"Psychoneuroendocrinology"},{"key":"10.1016\/j.ctrv.2024.102770_b0305","doi-asserted-by":"crossref","first-page":"956","DOI":"10.1038\/bjc.2016.71","article-title":"Adjuvant ovarian function suppression and cognitive function in women with breast cancer","volume":"114","author":"Phillips","year":"2016","journal-title":"Br J Cancer"},{"key":"10.1016\/j.ctrv.2024.102770_b0310","doi-asserted-by":"crossref","first-page":"1875","DOI":"10.1200\/JCO.19.01866","article-title":"Patient-reported cognitive impairment among women with early breast cancer randomly assigned to endocrine therapy alone versus chemoendocrine therapy: results from TAILORx","volume":"38","author":"Wagner","year":"2020","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ctrv.2024.102770_b0315","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1007\/s11764-019-00800-x","article-title":"Sexual health and rehabilitation after ovarian suppression treatment (SHARE-OS): a clinical intervention for young breast cancer survivors","volume":"14","author":"Bober","year":"2020","journal-title":"J Cancer Surviv"},{"key":"10.1016\/j.ctrv.2024.102770_b0320","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1007\/s10549-010-1332-y","article-title":"Monthly versus 3-monthly goserelin acetate treatment in pre-menopausal patients with estrogen receptor-positive early breast cancer","volume":"126","author":"Masuda","year":"2011","journal-title":"Breast Cancer Res Treat"},{"key":"10.1016\/j.ctrv.2024.102770_b0325","doi-asserted-by":"crossref","first-page":"771","DOI":"10.1007\/s12282-015-0637-4","article-title":"Phase 3, open-label, randomized study comparing 3-monthly with monthly goserelin in pre-menopausal women with estrogen receptor-positive advanced breast cancer","volume":"23","author":"Noguchi","year":"2016","journal-title":"Breast Cancer"},{"key":"10.1016\/j.ctrv.2024.102770_b0330","doi-asserted-by":"crossref","first-page":"S631","DOI":"10.1016\/j.annonc.2022.07.243","article-title":"209P Efficacy and feasibility of long acting every three months goserelin for premenopausal breast cancer patients during COVID pandemic","volume":"33","author":"El Zawawy","year":"2022","journal-title":"Ann Oncol"},{"key":"10.1016\/j.ctrv.2024.102770_b0340","doi-asserted-by":"crossref","DOI":"10.1016\/j.esmoop.2023.101335","article-title":"111P Goserelin 3 monthly depot is noninferior to goserelin monthly depot in the treatment of breast cancer: a real-world evidence study","volume":"8","author":"Wu","year":"2023","journal-title":"ESMO Open"},{"key":"10.1016\/j.ctrv.2024.102770_b0345","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1007\/s12282-016-0691-6","volume":"24","author":"Kurebayashi","year":"2017","journal-title":"Breast Cancer"},{"key":"10.1016\/j.ctrv.2024.102770_b0350","doi-asserted-by":"crossref","first-page":"e939","DOI":"10.1016\/j.clbc.2018.04.005","article-title":"Efficacy of different leuprolide administration schedules in premenopausal breast cancer: a retrospective review","volume":"18","author":"Kendzierski","year":"2018","journal-title":"Clin Breast Cancer"},{"key":"10.1016\/j.ctrv.2024.102770_b0355","doi-asserted-by":"crossref","first-page":"1584","DOI":"10.1200\/JCO.2015.61.2259","article-title":"Twelve-month estrogen levels in premenopausal women with hormone receptor-positive breast cancer receiving adjuvant triptorelin plus exemestane or tamoxifen in the suppression of ovarian function trial (SOFT): the SOFT-EST substudy","volume":"34","author":"Bellet","year":"2016","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ctrv.2024.102770_b0360","doi-asserted-by":"crossref","first-page":"e936","DOI":"10.1002\/onco.13722","article-title":"Measuring ovarian escape in premenopausal estrogen receptor-positive breast cancer patients on ovarian suppression therapy","volume":"26","author":"Burns","year":"2021","journal-title":"Oncologist"},{"key":"10.1016\/j.ctrv.2024.102770_b0365","doi-asserted-by":"crossref","first-page":"454","DOI":"10.1016\/j.clbc.2023.03.009","article-title":"Ovarian function suppression in premenopausal women with concurrent endocrine therapy use","volume":"23","author":"Fleege","year":"2023","journal-title":"Clin Breast Cancer"},{"key":"10.1016\/j.ctrv.2024.102770_b0370","doi-asserted-by":"crossref","first-page":"524","DOI":"10.1200\/JCO.2022.40.16_suppl.524","article-title":"Estradiol (E2) levels in premenopausal women with hormone receptor-positive (HR+) breast cancer (BC) on ovarian function suppression (OFS) with gonadotropin-releasing hormone agonists (GnRHa)","volume":"40","author":"Tesch","year":"2022","journal-title":"J Clin Oncol"}],"container-title":["Cancer Treatment Reviews"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0305737224000987?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0305737224000987?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,14]],"date-time":"2026-05-14T07:50:13Z","timestamp":1778745013000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0305737224000987"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,9]]},"references-count":73,"alternative-id":["S0305737224000987"],"URL":"https:\/\/doi.org\/10.1016\/j.ctrv.2024.102770","relation":{},"ISSN":["0305-7372"],"issn-type":[{"value":"0305-7372","type":"print"}],"subject":[],"published":{"date-parts":[[2024,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Revisiting ovarian function suppression with GnRH agonists for premenopausal women with breast cancer: Who should use and the impact on survival outcomes","name":"articletitle","label":"Article Title"},{"value":"Cancer Treatment Reviews","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ctrv.2024.102770","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 The Authors. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"102770"}}